作者:Toshiyuki Takahashi、Yuji Haga、Toshihiro Sakamoto、Minoru Moriya、Osamu Okamoto、Katsumasa Nonoshita、Takunobu Shibata、Takuya Suga、Hirobumi Takahashi、Tomoko Hirohashi、Aya Sakuraba、Akira Gomori、Hisashi Iwaasa、Tomoyuki Ohe、Akane Ishihara、Yasuyuki Ishii、Akio Kanatani、Takehiro Fukami
DOI:10.1016/j.bmcl.2009.05.013
日期:2009.7
Continuing medicinal chemistry studies to identify spiropiperidine-derived NPY Y5 receptor antagonists are described. Aryl urea derivatives of a variety of spiropiperidines were tested for their NPY Y5 receptor binding affinities. Of the spiropiperidines so far examined, spiro[3-oxoisobenzofurane-1(3H),4 '-piperidine] was a useful scaffold for producing orally active NPY Y5 receptor antagonists. Oral administration of 5c significantly inhibited the Y5 agonist-induced food intake in rats with a minimum effective dose of 3 mg/kg. In addition, this compound was efficacious in decreasing body weight in diet-induced obese mice. (C) 2009 Elsevier Ltd. All rights reserved.